Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015;14(14):2219-21.
doi: 10.1080/15384101.2015.1041695.

Precision oncology for patients with advanced cancer: the challenges of malignant snowflakes

Razelle Kurzrock  1 , Francis J Giles
Affiliations

Precision oncology for patients with advanced cancer: the challenges of malignant snowflakes

Razelle Kurzrock et al. Cell Cycle. 2015.

Abstract

Precision oncology implies customizing treatment to the unique molecular and biologic characteristics of each individual and their cancer. Its implementation is being facilitated by remarkable technological advances in genomic sequencing, as well as the increasing availability of targeted and immunotherapeutic drugs. Yet, next generation sequencing may be a disruptive technology in that its results suggest that classic paradigms for clinical research and practice are a poor fit with the complex reality encountered in metastatic malignancies. Indeed, it is evident that advanced tumors have heterogeneous molecular landscapes that mostly differ between patients. Traditional modes of clinical research/practice are drug centered, with a strategy of finding commonalities between patients so that they can be grouped together and treated similarly. However, if each patient with metastatic cancer has a unique molecular portfolio, a new patient-centered, N-of-one approach that utilizes individually tailored treatment is needed.

Keywords: cancer; genomics; precision oncology; targeted therapy.

PubMed Disclaimer

References

    1. Wheler JJ, Parker BA, Lee JJ, Atkins JT, Janku F, Tsimberidou AM, Zinner R, Subbiah V, Fu S, Schwab R, et al.. Unique molecular signatures as a hallmark of patients with metastatic breast cancer: implications for current treatment paradigms. Oncotarget 2014; 5(9):2349-54; PMID:24811890 - PMC - PubMed
    1. Kandoth C, McLellan MD, Vandin F, Ye K, Niu B, Lu C, Xie M, Zhang Q, McMichael JF, Wyczalkowski MA, et al.. Mutational landscape and significance across 12 major cancer types. Nature 2013; 502(7471):333-9; PMID:24132290; http://dx.doi.org/10.1038/nature12634 - DOI - PMC - PubMed
    1. Wheler JJ, Lee JJ, Kurzrock R. Unique Molecular Landscapes in Cancer: Implications for Individualized, Curated Drug Combinations. Cancer Res 2014; 74(24):7181-4; [Epub ahead of print]; PMID:25326492; http://dx.doi.org/10.1158/0008-5472.CAN-14-2329 - DOI - PMC - PubMed
    1. Shaw AT, Kim DW, Mehra R, Tan DS, Felip E, Chow LQ, Camidge DR, Vansteenkiste J, Sharma S, De Pas T, et al.. Ceritinib in ALK-rearranged non–small-cell lung cancer. N Engl J Med 2014; 370:1189-97; PMID:24670165; http://dx.doi.org/10.1056/NEJMoa1311107 - DOI - PMC - PubMed
    1. Charles L, Sawyers MD. Chronic myeloid leukemia. N Engl J Med 1999; 340:1330-40; PMID:10219069; http://dx.doi.org/10.1056/NEJM199904293401706 - DOI - PubMed

Publication types